Yarlagadda Babu - BioCryst Pharmaceuticals Insider

BCRX -- USA Stock  

USD 7.28  0.04  0.55%

  SVP
Dr. Yarlagadda S. Babu, Ph.D., serves as a Senior Vice President Drug Discovery of the company. Dr. Babu has served as the Companys Vice President Drug Discovery since 1992. In October of 2013, Dr. Babus title was changed to Senior Vice President of Drug Discovery. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham
Age: 64  SVP Since 2013  Ph.D    
919-859-1302  http://www.biocryst.com
Babu obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, U.K. before joining UAB. He has over 70 publications in peerreviewed journals, and a number of issued and pending patents to his credit.

Yarlagadda Babu Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (32.62) % which means that it has lost $32.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (224.59) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 51.69 M in liabilities with Debt to Equity (D/E) ratio of 111.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioCryst Pharmaceuticals has Current Ratio of 1.23 suggesting that it is in a questionable position to pay out its financial obligations when they are due.

Similar Executives

Found 3 records

SVP Since

David NovackDynavax Technologies Corporatio
2013
Bob BrownDicerna Pharmaceuticals
2012
Robert CoffmanDynavax Technologies Corporatio
2014

Entity Summary

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. BioCryst Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 85 people.BioCryst Pharmaceuticals (BCRX) is traded on BATS Exchange in USA. It is located in NORTH CAROLINA U.S.A and employs 85 people. BioCryst Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

BioCryst Pharmaceuticals Leadership Team

Rob Bennett, Vice President Investor Relations & Operations
Alane Barnes, VP, General Counsel and Corporate Secretary
Yarlagadda Babu, Sr. VP of Drug Discovery
Fred Cohen, Director
Stanley Erck, Independent Director
George Abercrombie, Non-Executive Independent Chairman of the Board
Robert Ingram, Director
Thomas Staab, CFO, Senior Vice President Principal Accounting Officer, Treasurer
Charles Sanders, Independent Director
Jon Stonehouse, CEO and President and Executive Director
Lynne Powell, Senior Vice President Chief Commercial Officer
Sanj Patel, Director
Kenneth Lee, Independent Director
William Sheridan, Senior Vice President Chief Medical Officer
Nancy Hutson, Independent Director

Stock Performance Indicators

Current Sentiment - BCRX

BioCryst Pharmaceuticals Investor Sentiment

Most of Macroaxis users are currently bullish on BioCryst Pharmaceuticals. What is your opinion about investing in BioCryst Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

BioCryst Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Search macroaxis.com